In this Build Your Own Case Study | Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community, learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided with patient clinical presentation and other relevant factors including age, time and aggressiveness of relapse, social history, genetic profiling/molecular testing results, cytogenetic risk factors, disease subtype, comorbidities, and prior therapies in order to make appropriate treatment decisions. Expert faculty will discuss participant selection of treatments, sequencing considerations, and drug-related toxicities. The activity will conclude with a discussion on how to develop strategies to assist patients with coordinated care and long-term disease management after the receipt of CAR T-cell therapy.
This ancillary educational activity is derived from the 2024 ASCO Annual Meeting, originally held on May 31, 2024
Speakers
Christopher Flowers, MD, MS, FASCO
Division Head, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX, USA
Christopher Flowers, M.D., joined The University of Texas MD Anderson Cancer Center in August 2019 as Department Chair of Lymphoma/Myeloma and was appointed Division Head of Cancer Medicine in September 2023. Prior to MD Anderson, he was professor of Hematology and Oncology with a joint appointment in Biomedical Informatics at Emory University School of Medicine in Atlanta. During his tenure there, he served the Winship Cancer Institute as director of the Emory Healthcare-Lymphoma Program for 13 years and as scientific director of Research Informatics for four years. An internationally recognized expert in lymphoma clinical care, epidemiology and outcomes research, Dr. Flowers is an innovator who has a passion for facilitating new drug development. He is an active clinician who conducts clinical research involving cancer outcomes, cancer informatics, and phase 1/2 trials, focusing on the clinical development of novel therapeutics for B-cell lymphomas. His broader research interests include patient-oriented research in lymphoma and computer microsimulation models and cost-effectiveness analyses aimed at developing strategies to individualize care for cancer patients and improve systems of care. His work has resulted in >200 peer-reviewed publications. He has received peer-reviewed funding from foundations and the NIH including leading two U01 awards and two multi-institutional team science grants.
Dr. Flowers earned his medical degree from Stanford University School of Medicine where he also completed an MSc in Medical Informatics to gain expertise developing information systems to improve clinical research. He completed his internship and residency in Internal Medicine from the University of Washington in Seattle, where he continued his research training as a fellow in the Robert Wood Johnson Clinical Scholars Program and earned a second master’s degree in Pharmaceutical Outcomes Research and Policy. During this time, he also completed his fellowship in Medical Oncology from the Fred Hutchinson Cancer Research Center. Dr. Flowers has served in many capacities for national professional societies and was elected to membership in the American Society of Clinical Investigation. In 2018, he was named a Fellow of the American Society of Clinical Oncology (ASCO), and served as chair of both the ASCO guidelines on management of febrile neutropenia and ASCO health disparities committees.
Catherine Coombs, MD
Associate Clinical Professor
Division of Hematology-Oncology
Department of Medicine
University of California, Irvine School of Medicine
Orange, CA, USA
Dr. Catherine Coombs is currently an Associate Clinical Professor at the University of California Irvine. She attended medical school at the University of Cincinnati College of Medicine. She completed her internship and residency at Duke University Medical Center in Durham. She subsequently completed a hematology and oncology fellowship at Memorial Sloan Kettering Cancer Center. She led the CLL program as an Assistant Professor at the University of North Carolina prior to moving to California in 2022 to be closer to family. Her primary clinical focus is in the care of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. She has participated in multicenter studies examining the “real-world” implications of novel therapeutic agents on the lives of patients and has served as an investigator on a number of clinical trials, including both cooperative group studies and early-phase trials of novel agents. In addition to CLL, she sees other non-acute leukemias and has expertise in leukemia precursor states including clonal hematopoiesis (or “CHIP”) and CCUS.
Paolo Fabrizio Caimi, MD
Associate Professor
Cleveland Clinic Lerner College of Medicine
Staff Physician, Department of Hematology and Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH, USA
Dr. Paolo Caimi is an associate professor at the Case Western Reserve University School of Medicine and a hematologist/oncologist at University Hospital (UH) Cleveland Medical Center. In addition to CLL, he specializes in Hodgkin and Non-Hodgkin lymphoma and other hematopoietic malignancies. He received his MD at Pontificia Universidad Catolica de Chile and completed his residency at Johns Hopkins University. His area of expertise includes stem cell transplants and bone marrow transplantation.
Accreditation and Disclosure Information
Target Audience
This activity is intended for hematologists/oncologists (community and academic), PAs, NPs, and other members of the interprofessional, multidisciplinary cancer care team on a global level that interface with patients with NHL.
Educational Objectives
After completing this activity, the participant should be better able to:
- Assess the expanding treatment landscape for patients with NHL, including new and emerging non-CART options such as bispecific antibodies, and its impact on individualized treatment selection and treatment sequencing.
- Analyze available CAR T-cell therapies for patients with relapsed/refractory NHL based on the latest safety and efficacy trial data and currently approved indications.
- Conduct comprehensive evaluation to determine eligibility and potential benefits of CAR T-cell therapy based on recent clinical trial data, guideline recommendations, as well as patient-, disease-, and treatment-specific factors.
- Identify suitable candidates that might benefit from CAR T-cell therapy in an outpatient setting versus an inpatient setting to support patient preference and satisfaction.
- Apply a multidisciplinary approach to coordinate care between referring physician, establishing outpatient CART centers, and cross-collaboration with clinical teams to ensure individualized and optimal patient management.
Agenda
- Exploring Innovative NHL Treatment Alternatives: Expert Insights on Integrating Clinical Guidelines into Decision-Making
- Constructing Patient Case Studies: Expert Conversations on Selecting Treatment Options and Patient Scenarios
- Cultivating Personalized Treatment Strategies through a Multidisciplinary Approach: Expert Discourse on Coordinated Care, Outpatient CAR T, and Patient-Centric Factors
- Key Takeaways and Conclusions
- Q&A with Expert Faculty
This activity is provided by MLI
Accreditation and Credit Statements
In support of improving patient care, Medical Learning Institute Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
EBAH Credit
Medical Learning Institute Inc. is an accredited CME-CPD provider by the European Board for Accreditation in Hematology (EBAH).
This educational activity has been accredited for a maximum number of 1.0 EBAH CME-CPD credits. Each participant should only collect credits for time that she/he actually spent in the educational activity.
How to collect your EBAH CME credits:
You can also use the direct link to the account creation / login page:
https://www.pe-online.org/subscribe/SPE006_PR_Subscribe.aspx?taalID=61&CalendarPopUp=&PID=343
- Creating a CME account or logging in is simple and free of cost.
- Please inform your details to event organizer, so they can add your EBAH-CME credit points.
Within the EBAH-CME system, you can:
- Print your EBAH-CME certificates.
- Review and manage your personal account.
- Search for accredited events based on the European Hematology Curriculum.
For further assistance please contact:
EBAH Office Koninginnegracht 12b, 2514 AA – The Hague, The Netherlands
Phone: +31 (0)70 3020 099
Email: info@ebah.org
ECMEC® Credit
The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credits™into European CME credit (ECMEC®) should contact the UEMS (www.uems.eu).
PA
Medical Learning Institute Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until June 14, 2025. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.65 contact hour in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Support Statement
This activity is supported by an educational grant from Bristol Myers Squibb.
Disclosure & Conflict of Interest Policy
Medical Learning Institute Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
Christopher Flowers, MD, MS, FASCO
Division Head ad Interim, Division of Cancer Medicine
Department Chair, Department of Lymphoma-Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX, USA
Christopher Flowers, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, N-Power Medicine, Pharmacyclics/Janssen
Research funding: 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceutical, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research
Stock Options: Foresight Diagnostics (Advisor w/individual stock options), N Power (Advisor w/individual stock options)
Planner/Presenter
Catherine Coombs, MD
Associate Clinical Professor
Division of Hematology-Oncology
Department of Medicine
University of California, Irvine School of Medicine
Orange, CA, USA
Catherine Coombs, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: AbbVie, Allogene, AstraZeneca, BeiGene, Janssen, Genentech, Lilly, MEI Pharma, Mingsight, Octapharma
Speakers’ Bureau: AbbVie, AstraZeneca, BeiGene, Genentech, Lilly
Research funding: AbbVie, CarnaBio, Lilly
Own stock: Pfizer, bluebird bio, Geron
The following relationships have ended within the last 24 months:
Consultant/Advisor: Allogene, Mingsight
Planner/Presenter
Paolo F. Caimi, MD
Associate Professor
Cleveland Clinic Lerner College of Medicine
Staff Physician, Department of Hematology and Oncology
Cleveland Taussig Cancer Institute
Cleveland, OH, USA
Paolo F. Caimi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Arvinas, Bristol Myers Squibb, Genentech, Novartis, Takeda, Sobi, Recordati Rare Diseases
Research funding: AbbVie, ADC Therapeutics, Genentech, Genmab, Recordati Rare Diseases
The following relationships have ended within the last 24 months:
Consultant/Advisor: ADC Therapeutics
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
For Physicians, if requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
About This Activity
Medical Learning Institute Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by an educational grant subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc. or any of its partners, providers, and/or supporters.
Copyright © 2024 Medical Learning Institute Inc | All Rights Reserved